AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Epitope mimic for human HIV-neutralizing antibody 2G12 synthesized.
2004 MAY 5 - (NewsRx.com & NewsRx.net) -- Scientists have synthesized a template-assembled oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12.
According to published research from the United States, "The synthesis and antibody-binding affinity of a novel template-assembled oligomannose cluster as an epitope mimic for human anti-HIV antibody 2G12 are described. Cholic acid was chosen as the scaffold and three high-mannose type oligosaccharide (Man[subscript]9GlcNAc[subscript]2Asn) moieties were selectively attached at the 3alpha, 7alpha, and 12alpha-positions of the scaffold through a series of regioselective transformations.
"Binding studies revealed that the synthetic oligosaccharide cluster is 46-fold more effective than the subunit Man[subscript]9GlcNAc[subscript]2Asn in inhibiting 2G12-binding to immobilized gp120," reported Hengguang Li and Lai-Xi Wang at the University of Maryland. "The scaffold approach described in this paper provides an avenue to designing more effective epitope ...
- Epitope mimic for human HIV-neutralizing antibody 2G12 synthesized.
- Newspaper article from: AIDS Vaccine Week May 3, 2004 700+ words
...oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12...oligomannose cluster as an epitope mimic for human anti-HIV antibody...oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12...
- HUMAN HIV STUDY WITH HGP-30 SHOWS SIGNIFICANTLY INCREASED LEVEL OF PROTECTION...
- Press release article from: PR Newswire March 13, 1996 700+ words
ALEXANDRIA, Va., March 13 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq: CELI, CELIW) and University of Nebraska Medical Center today announced promising results from a booster immunization clinical study with the HGP-30 AIDS immunogen. Five (5) out of five (5) volunteers tested who had been
- Epicyte Pharmaceutical Advances Production of Human HIV Antibodies in Plants.
- Press release article from: Business Wire January 28, 2003 700+ words
Business Editors & Health/Medical Writers BIOWIRE2K SAN DIEGOBUSINESS WIREJan. 28, 2003 San Diego Biopharmaceutical Company Takes Antibody Production from Cell Culture to Plants to Prevent HIV Transmission Epicyte Pharmaceutical, Inc., a San Diego biopharmaceutical company focused on the
- Medizone Signs Letters of Intent to Commence Human HIV/AIDS Clinical Trials in...
- Press release article from: PR Newswire December 2, 1997 700+ words
Improved Ozone Technology Delivery System to Enhance Market Potential SALT LAKE CITY, Dec. 2 /PRNewswire/ -- Medizone International, Inc. (Bulletin Board: MZEI.U) ("Medizone") announced today that it will begin an aggressive clinical trial program in Italy during the second quarter of 1998, with an
- GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA.
- Press release article from: PR Newswire February 20, 2009 700+ words
Trials in South America to Follow ATLANTA, Feb. 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (BULLETIN BOARD: GOVX) , an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents,
- HIV-VAC, Inc. Explores Feasibility of Human HIV/AIDS Trials in Africa.
- Press release article from: Business Wire June 2, 2000 700+ words
Business Editors/Health & Medical Writers TORONTOBUSINESS WIREJune 2, 2000 HIV-VAC, Inc, (OTC/BB: HIVC) announced today that it is working towards initiating human trials in one or more African countries where HIV/AIDS has reached epidemic proportions. These new trials in Africa would
- Spaltudaq Corp. Announces Identification of Broadly and Potently Neutralizing...
- Newspaper article from: AIDS Vaccine Week April 13, 2009 700+ words
Theraclone Sciences, a biopharmaceutical company formerly known as Spaltudaq, focused on the discovery and development of human antibodies, announced results from its HIV antibody discovery program at the HIV Immunobiology Meeting of the Keystone Symposia Global Health Series earlier this week (see
- Defense Peptide Found in Primates May Block Some Human HIV Transmissions.
- News wire article from: AScribe Medicine News Service August 9, 2006 700+ words
Byline: University of Central Florida ORLANDO, Fla., Aug. 9 (AScribe Newswire) -- As primates evolved 7 million years ago, the more advanced species stopped making a protein that University of Central Florida researchers believe can effectively block the HIV-1 virus from entering and infecting
Source: HighBeam Research, Epitope mimic for human HIV-neutralizing antibody 2G12 synthesized.